Sphere Fluidics introduces Cyto-Cellect Human IgGK Detection Kit
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, today introduced the Cyto-Cellect™ Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System for rapid and cost-effective measurement of antibody class and productivity in cell line development.
Sphere Fluidics introduces latest version of Cyto-Mine Studio Software Suite
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, today introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis. The latest software version includes new functionality to…
Sphere Fluidics expands into additional facility at Granta Park
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new office space at Granta Park in Cambridgeshire, UK. The new facilities support the Company’s accelerated expansion and accommodate its plans for further growth.
CPI to showcase results from BioStreamline project developing novel biotherapeutics
CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project - featuring technology from Sphere Fluidics and Horizon Discovery Group - to optimise the development of novel therapeutics.
Sphere Fluidics closes a $4.8 million USD (£3.7 million) funding round
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment.
Fujifilm announces the introduction of a 10 week cell line development timeline
FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organisation (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
Sphere Fluidics hires 10 new UK and US staff in its plan to scale internationally
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed six new employees and plans to hire four more staff in its UK and US sites.
Oxford Genetics and Sphere Fluidics announce a multi-partner collaboration for gene editing
Oxford Genetics and Sphere Fluidics announce a multi-partner collaboration to expedite the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cell lines.
Sphere Fluidics closes $2m (£1.5m) investment round
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed a $2 million (circa £1.5 million) investment round.
Sphere Fluidics collaborates with Peak Analysis and Automation
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leader in the industry for the design and manufacture of automated laboratory equipment, will collaborate to offer automated micro-plate handling capabilities for single cell analysis.
Sphere Fluidics introduces new Cyto-Mine Studio Software Suite
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, today introduced Cyto-Mine® Studio Software Suite, an updated software for its innovative Cyto-Mine Single Cell Analysis System.
Sphere Fluidics appoints Dr Tris Vaughan as scientific advisor
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, announced that Tris Vaughan, PhD FRSB has joined its scientific advisory board (SAB).
Sphere Fluidics expands Cyto-Mine sales networks and distribution in US, Europe and Asia
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, has today announced the expansion of its international commercial operations.
Sphere Fluidics and Geneva Biotech receive Eurostars genome editing grant
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, and Geneva Biotech, an EMBL spin-out developing world-class viral and non-viral DNA delivery systems, have received a €1.6 million grant from Eurostars. The funding will be used to develop large DNA cargo gene delivery and genome engineering systems.
Sphere Fluidics' Cyto-Mine wins major European Product Innovation award
Sphere Fluidics’ Cyto-Mine has won a Frost and Sullivan 2017 European Product Innovation award.
Sphere Fluidics e-commerce site allows researchers rapid access to microfluidic products
Sphere Fluidics Limited (SF), an established Life Sciences tools company, today announced the launch of its new E-Commerce website platform to enable researchers easy access to its specialist microfluidic products.
Sphere Fluidics appoints new R&D executive
Sphere Fluidics, the single cell analysis and characterisation company, has hired Dr Marian Rehak as their new R&D Director.
Sphere Fluidics relocates to new larger facility at Babraham Research Campus
Sphere Fluidics has relocated to its new integrated lab and office space at the Jonas Webb Building on Babraham Research Campus.
Dr Rob Marchmont joins Sphere Fluidics as new Commercial Director
Dr Rob Marchmont, who previously held Senior commercial positions at NanoInk and GE Healthcare and has more than 25 years' experience in the Life Sciences market, has now joined Sphere Fluidics, to help further grow the business, as their new Commercial Director.
Founders win European ACES Entrepreneurial Prize for Best University Life Sciences Spin-Out
Professors Chris Abell and Wilhelm Huck of Cambridge University and Radboud University, Nijmegen respectively were awarded an international prize for their enterprise in creating and developing Sphere Fluidics.
Sphere Fluidics successfully closes a £1.6 million Series A investment round
Sphere Fluidics, an early-stage, Cambridge-based company focusing on developing novel products and services for single cell analysis, has just completed a £1.6 million investment round.